Introduction

Congenital anomalies of the kidney and urinary tract (CAKUT) account for more than 50% of the abdominal masses found in neonates and involve about 0.5% of all pregnancies\(^1\). Despite recent advances in prenatal diagnosis and early surgical intervention, these diseases still remain the primary cause of kidney failure in infants and children. Registry data from across the world, regarding the primary renal disease-mediated development of end-stage renal failure in children show that approximately 50% of the cases are due to CAKUT\(^2,3\), and increasing evidence suggests that these abnormalities predispose children to hypertension and cardiovascular disease during adulthood\(^4\).

A wide spectrum of diseases is encompassed by the term “CAKUT,” including kidney anomalies such as aplasia, hypoplasia, and multicystic dysplastic kidneys; ureteric anomalies such as megaureter, ureteropelvic junction obstruction, ureterovesical junction obstruction or incompetence, and duplex kidneys/ureters; and anomalies of the bladder and urethra\(^5\), a group that reflects the common causes of these malformations. These anomalies have a familial pattern, involving incomplete and variable penetrance, often leading to the production of different anatomical patterns. Therefore, these assorted structural anomalies have been speculated to share a common pathogenic mechanism and genetic background\(^6\).

Renal functional impairment may develop postnatally from bacterial pyelonephritis and/or persistent urinary flow impairment causing renal atrophy and fibrosis, but the primary “hit” in CAKUT is clearly a developmental one, resulting in renal dysplasia\(^7\). Recently, diverse developmental anomalies of the kidney corresponding to defects at a particular stage of development have been reported (Table 1).

Normal development of the human kidney begins at the fifth week of gestation when the ureteric bud extends from the mesonephric duct into the metanephric blastema. Development
of the kidney requires complex interactions between epithelial cells in the ureteric bud and the surrounding mesenchymal cells; these interactions result in controlled cell proliferation, death, and differentiation. The ureteric bud branches serially and differentiates into the collecting ducts and ureter, with the distal end forming the bladder trigone. Meanwhile, a part of the mesenchyme undergoes epithelial conversion to form the nephron from the glomerulus to the distal tubules, with the remainder developing into the supporting renal interstitium. Ureteric bud induction and differentiation is now known to depend on the interactions mediated by growth factors, matrix molecules, and transcriptional factors that control the expression of these genes.\(^5\)

### Ureter induction

1. **Renal agenesis**

   The most crucial event in kidney development is the first signaling process that induces the outgrowth of the ureter from the mesonephric duct. Central to the induction process is the expression of the signaling molecule glial cell line-derived neurotropic factor (GDNF), which is released from the mesenchyme and binds to its receptors, namely, receptor tyrosine kinase (RET) and GDNF-family receptor α1 (GFRA1), in the mesonephric duct.\(^8, 9\) After binding to its receptors RET and GFRA1, GDNF activates a signaling cascade that eventually leads to epithelial cell proliferation and epithelial branching.\(^8, 10\) Thus, the failure of GDNF-RET signaling is reported to be linked to renal agenesis. Renal defect in \(Gfra1\) knockout mice has been reported\(^11\), but mutations in \(GDNF\) or \(RET\) have not been found in human patients with kidney defects. This could be because human kidney development is not susceptible to slight reduction in protein level that results from heterozygous inactivation, and homozygous mutations can escape detection because of embryonic lethality.\(^4\) However, mutations in eyes-absent homologue 1 (\(EYA1\)), sine oculis homeobox homologue 1 (\(SIX1\)), and \(SIX5\)–the 3 regulators of GDNF–result in branchiooetoorenal syndrome.\(^12\) Outside of the metanephric mesenchyme, the signaling molecule bone morphogenetic protein 4 (\(BMP4\)) inhibits GDNF activity, and the expression of gremlin 1 (\(GREM1\)) leads to the inactivation of \(BMP4\). Thus, mice carrying mutations in \(Grem1\) show renal agenesis due to \(Bmp4\)-mediated inhibition of Gdnf signaling\(^13\), and mutations in \(BMP4\) have been reported in human renal hypoplasia patients.\(^14\)

2. **Ureter malformation**

   Receptor tyrosine kinase antagonist sprouty 1 (\(SPRY1\)) acts downstream of GDNF by inhibiting intracellular RET signaling; mutations in this gene result in ectopic ureters by rendering the duct more sensitive to GDNF.\(^35\)

   Forkhead box protein C1 (\(FOXC1\)), slit homologue 2 (\(SLIT2\)), and its receptor roundabout homologue 2 (\(ROBO2\)) have been reported to confine GDNF expression to the caudal part of the nephric cord in mice studies.\(^16\) and mutations in genes encoding these proteins lead to an expansion of GDNF expression to the rostral part, resulting in multiple ureters. Particularly, missense mutations of \(ROBO2\) have been reported to be associated with vesicoureteral reflux (\(VUR\)).\(^17, 18\)

   Primary \(VUR\) is a common disease, occurring with an incidence of approximately one in 100 infants, and it accounts for a high familial occurrence with a prevalence of 27-50% among siblings and offspring of patients, indicating autosomal dominant inheritance with reduced penetrance.\(^18\) At present, \(VUR\) has been widely accepted as a genetically heterogeneous disorder, and genes participating in ureter induction are under investigation.

### Ureteric bud branching

1. **Renal hypoplasia**

   The ureteric bud branches serially, and nephrons are induced by a signal from the tip of the ureter. Because the kidney size is primarily determined by the total number of nephrons formed during the development, defect in the ureteric bud branching results in reduced nephron number and functional renal tissue. Recent studies have shown that there is a strong correlation between
the number of nephrons and the risk of primary hypertension, with
the average hypertensive patients having 46% fewer glomeruli than
those in normotensive individuals, supporting the hyperfiltration
hypothesis.

Growth of the ureter requires continuous inductive signals from
the mesenchyme. WNT11, which is produced by the ureteric
bud tips, seems to complete a feedback loop that acts on the
mesenchyme to promote GDNF expression, and mutations that
inactivate Wnt11 lead to the development of kidneys that are 36%
smaller than those of the wild type. Similarly, a reduction in
GDNF-RET signaling results in reduced amounts of WNT11,
and removing one copy of WNT11 and RET further aggravates
the hypoplastic kidney phenotype.

GDNF-RET signaling is very crucial; mutations that affect
the expression of transcriptional regulators of these genes also result in
reduced ureter branching, and heterozygous mutations in paired-
box protein 2 (PAX2), which activates the expression of both
reduced ureter branching, and heterozygous mutations in paired-
box protein 2 (PAX2), which activates the expression of both
GDNF and RET, cause renal coloboma syndrome in humans.

Patterning

The first glomeruli form at 8-9 weeks of gestation, and new
nephrons are added at the outer layer of the cortex until 32-36
weeks. On induction, nephron precursor cells condense to form a
cap structure that surrounds the ureter. These cells then undergo a
mesenchyme-to-epithelial transition to form the renal vesicle, which
develops into a comma-shaped body and then an S-shaped body.
The S-shaped body elongates and differentiates into the various
segments of a nephron. Each nephron segment fulfills particular
physiological functions, such as blood filtration, pH regulation,
and reabsorption and secretion of solutes. Gene expression patterns
are segment specific, and defects at this stage of development result
in specific glomerular and tubular diseases, but knowledge on the
regulatory program that leads to nephron segmentation is limited.

Podocyte cells mature under the control of transcription factors such as Wilms’ tumor transcription factor (WT1). WT1
in presumptive podocyte layer induces vascular growth through
the activation of vascular endothelial growth factor (VEGF)
that attracts endothelial cells, which in turn produce platelet-
derived growth factor (PDGF) that supports the differentiation of
mesangial cells. Hence, WT1 mutation in humans is associated
with diffuse mesangial sclerosis in Denys-Drash syndrome. Terminal differentiation of the podocyte layer requires the
regulation of LIM homeobox transcriptional factor 1β (LMX1B),
and lack of LMX1B interferes with the expression of podocyte-
specific genes, mutations in which cause nail-patella syndrome.

CAKUT phenotype

Recently, there have been enormous advances in the field
of kidney development, and genes functioning at specific
developmental stages have been identified. However, expression
patterns are not always restricted to a single cell lineage, and
phenotypes can vary greatly depending on the type of mutation in
a particular gene.

The critical role of rennin-angiotensin system (RAS) during
kidney development is widely accepted, and mutations in the genes
encoding components of the RAS or pharmacological inhibition
of RAS results in diverse malformations of the kidney and urinary
tract. Of the 2 receptors for angiotensin II, angiotensin type 2
receptor has been recently recognized, and its gene AGTR2 is
primarily an embryonic gene, which is actively transcribed from
the onset and throughout the embryonic development of the
kidney and urinary tract system. It has been reported that in
Agtr2 mutant mice, a wide anatomical spectrum of anomalies
are randomly noted in the same pedigree, with each specific
anatomical pattern having its own counterpart in humans. WT1
is required for ureter induction, formation of the nephron, and
for differentiation and maintenance of the glomerulus. Hence,
mice carrying Wt1 mutations lack kidneys, show renal dysplasia,
and develop renal failure at adulthood. Point mutations that affect
specific sites of the RET protein lead to a wide range of CAKUT
phenotypes, probably because point mutations might specifically
affect the interactions of the RET protein with other regulatory
proteins, leading to the development of a diverse spectrum of
phenotypes. Therefore, genotype-phenotype studies of CAKUT at
a large scale will be required to provide a clue for the investigation of
kidney development.

Cystic kidney disease

Cystic diseases of the kidney (CDK) are a group of distinctive
kidney diseases, leading to the formation of dilated tubules or
cysts. They are among the most frequent genetic lethal diseases
in humans. Autosomal dominant forms of CDK, the most
prominent example of which is autosomal dominant polycystic
kidney disease (ADPKD), are characterized by end-stage renal
disease (ESRD) in adulthood. Autosomal recessive form of CDK,
such as nephronophthisis (NPHP) and autosomal recessive
polycystic kidney disease (ARPKD), cause ESRD in childhood or
adolescence.

By positional cloning, the first 2 genes that have been implicated
in CDK–polycystic kidney disease 1 and 2 (PKD1 and PKD2),
which encode the proteins polycystin1 and 2, respectively—have been identified. The 2 proteins have a role in the maintenance of renal tubular cell differentiation. ARPKD is characterized by bilateral renal cystic enlargement; most patients develop ESRD in infancy, early childhood, or adolescence. By using positional cloning, researchers identified polycystic kidney and hepatic disease 1 (PKHD1), which encodes a novel protein fibrocystin/polyductin that has a role in terminal differentiation of the collecting duct and biliary systems. NPHP is an autosomal recessive cystic kidney disease and the most frequent genetic cause for ESRD in the first 3 decades of life. Unlike PKD, cysts in ESRD are mostly restricted to the corticomedullary border of the kidneys, and kidney sizes are reduced or normal. In all, 5 NPHP-associated genes, NPHP1-NPHP5, have been identified by positional cloning; these genes encode nephrocystin proteins, nephrocystin 1-nephrocystin 5, respectively. These proteins are involved in cell-cell and cell-matrix adhesion signaling events and in cell division. Nevertheless, the molecular link between these functions and the development of renal cysts remains elusive.

Despite their clinical and pathological heterogeneity, the similar outcome of cyst formation has led to the assumption that gene defects in each of these disorders may disrupt a common pathway. Recent studies revealed that cystoproteins, the products of cystic kidney disease genes, are expressed in the sensory organelles known as primary cilia, in the basal bodies or centrosomes. Primary cilia link mechanosensory, visual, osmotic, gustatory, and other stimuli to the mechanisms of cell-cycle control and epithelial cell polarity. The link between the cilium and centriole suggests a mechanism underlying cilial sensing required to maintain the growth-arrested phenotype of mature tubules.

The pathogenic link between cystoprotein expression in the cilia and the renal cystic phenotype remains unknown, and one of the CDK variants medullary cystic kidney disease 2 (MCDK2) is caused by mutations in uromodulin (UMOD); the expression of this gene has not been thus far found in the cilia, basal bodies, or centrosomes. Nevertheless, this “ciliopathy” model for explaining the mechanisms underlying various cystic diseases in the unifying theory is an attractive hypothesis.

**Renal dysplasia**

Dysplastic kidneys are abnormally developed kidneys with poorly branched/differentiated nephrons and collecting ducts, increased stroma and occasional cysts, and metaplastic tissues, such as cartilage. Although many dysplastic kidneys develop by chance, some underlying causes, including genetic defects, lower urinary tract obstruction, and teratogen/drugs, might also exist. These conditions are not mutually exclusive and may occur simultaneously. Multicystic dysplastic kidneys (MCDK) are classically associated with non-patent ureters and obstruction, perhaps reflecting improper ureteric canalization. Animal studies in fetal sheep and mice suggest that postnatal urinary tract obstruction mimic human dysplastic kidneys, but the size of the cysts is never as large as that in MCDK, metaplastic cartilage does not form, and there is marked inflammation in the postnatal models, suggesting that other factors besides flow impairment are implicated in MCDK, and that not all human dysplasia are associated with obstruction. Serial ultrasonography examinations before and after birth indicate that MCDK can enlarge and involute into an “aplastic” phenotype. Involution may represent an imbalance of programmed cell death and growth by proliferation because apoptosis in human dysplasia is prominent, especially in the stroma around the dysplastic tubules. Recent studies showed that disordered expression of diverse growth factors, cell survival genes, and transcription factor genes correlate with disordered cell turnover and maturation, resulting in excessive growth followed by apoptotic involution. Thus, renal dysplasia is considered as a dynamic disorder associated with abnormal kidney development. Upregulated proliferation occurs in human dysplastic epithelia, which may be critical for cyst formation, whereas there is excess apoptosis in the adjacent mesenchyme, which may be responsible for the adequate involution of dysplastic kidneys. These aberrant patterns of proliferation and cell death may partially be explained by abnormal expression of key nephrogenic molecules such as the transcription factor hepatocyte nuclear factor-1β (HNF-1β) and other growth factors, survival molecules, or adhesion/matrix-associated proteins.

HNF-1β, first identified as a liver-specific transcription factor, is also highly expressed in other epithelial organs, including kidneys and pancreas; in the kidney, HNF-1β is restricted to the epithelial cells comprising renal tubules and collecting duct. Mutations in the genes encoding HNF-1β produce an autosomal dominant disorder maturity-onset diabetes of the young, type 5 (MODY5), also known as renal cysts and diabetes (RCAD), because affected individuals present with severe cystic kidney disease. Recently, mutations in HNF-1β have been identified in children with sporadic renal hypoplasia/dysplasia and are known to be a frequent cause of bilateral hyperechogenic kidneys detected by prenatal ultrasonography.

Besides HNF-1β, many individual components of dysplastic kidney have been reported, such as PAX2 and uroplakins, but some studies also report of children with compound heterozygote
mutations in several renal developmental genes. Therefore, interactions between different factors need to be identified, and probably dynamic models of gene networks will have to be considered to understand these complex developmental processes.

**Conclusion**

In recent years, there have been enormous advances in our knowledge regarding human kidney development; however, more research is required to understand the molecular networks underlying kidney development. From an epithelial bud and a loose aggregate of mesodermal cells to a completely functional kidney, a fine tuning of network is needed, and the investigation of this networking will provide a clue to the therapeutic intervention for CAKUT.

**References**

1. Scott JE, Renwick M. Antenatal diagnosis of congenital abnormalities in the urinary tract. Results from the Northern Region Fetal Abnormality Survey. Br J Urol 1988;62:295-300.
2. Neild GH. What do we know about chronic renal failure in young adults? I. Primary renal disease. Pediatr Nephrol 2009;24:1913-9.
3. Neild GH. What do we know about chronic renal failure in young adults? II. Adult outcome of pediatric renal disease. Pediatr Nephrol 2009;24:1921-8.
4. Schedl A. Renal abnormalities and their developmental origin. Nat Rev Genet 2007;8:791-802.
5. Woolf AS, Price KL, Scambler PJ, Winyard PJ. Evolving concepts in the urinary tract. Results from the Northern Region Fetal Abnormality Survey. Br J Urol 1988;62:295-300.
6. Ichikawa I, Kuwayama F, Pope JCt, Stephens FD, Miyazaki Y. Paradigm shift from classic anatomic theories to contemporary cell biological views of CAKUT. Kidney Int 2002;61:889-98.
7. Winyard P, Chitty LS. Dysplastic kidneys. Semin Fetal Neonatal Med 2008;13:142-51.
8. Costantini F, Shaya R. GDNF/Ret signaling and the development of the kidney. Bioessays 2006;28:117-27.
9. Dressler GR. The cellular basis of kidney development. Annu Rev Cell Dev Biol 2006;22:509-29.
10. Shaya R, Watanabe T, Costantini F. The role of GDNF/Ret signaling in ureteric bud cell fate and branching morphogenesis. Dev Cell 2005;8:65-74.
11. Calacano G, Farinas I, Wang LC, Hagler K, Forgie A, Moore M, et al. GFRA1 alpha1 is an essential receptor component for GDNF in the developing nervous system and kidney. Neuron 1998;21:53-62.
12. Ruf RG, Xu PX, Silvius D, Otto EA, Beckmann F, Muehr UB, et al. SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1-SIX1-DNA complexes. Proc Natl Acad Sci USA 2004;101:8090-5.
13. Michos O, Goncalves A, Lopez-Rios J, Tiecke E, Naillar F, Beier K, et al. Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and GDNF/WNT11 feedback signalling during kidney branching morphogenesis. Development 2007;134:2397-405.
14. Weber S, Taylor JC, Winyard P, Baker KF, Sullivan-Brown J, Schild R, et al. SIX2 and BMP4 mutations associate with anomalous kidney development. J Am Soc Nephrol 2008;19:891-903.
15. Basson MA, Watson-Johnson J, Shaya R, Akhulut S, Hyink D, Costantini FD, et al. Branching morphogenesis of the ureteric epithelium during kidney development is coordinated by the opposing functions of GDNF and Sprouty1. Dev Biol 2006;299:466-77.
16. Grieshammer U, Le M, Plump AS, Wang F, Tessier-Lavigne M, Martin GR. SLIT2-mediated ROBO2 signaling restricts kidney inductive to a single site. Dev Cell 2004;6:709-17.
17. Lu W, van Eerde AM, Fan X, Quintero-Rivera F, Kulkarni S, Ferguson H, et al. Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflex. Am J Hum Genet 2007;80:616-32.
18. Bertoli-Avellia AM, Conte ML, Punzo F, de Graaf BM, Lama G, La Manna A, et al. ROBO2 gene variants are associated with familial vesicoureteral reflux. J Am Soc Nephrol 2008;19:825-31.
19. Cordell HJ, Darlay R, Charoen P, Stewart A, Gullett AM, Lambert HJ, et al. Whole-genome linkage and association scan in primary, nonsyndromic vesicoureteric reflex. J Am Soc Nephrol 2010;21:113-23.
20. Murawski IJ, Gupta IR. Vesicoureteric reflux and renal malformations: a developmental problem. Clin Genet 2006;69:105-17.
21. Keller G, Zimmer G, Mall G, Ritz E, Amann K. Nephron number in patients with primary hypertension. N Engl J Med 2003;348:101-8.
22. Brenner BM, Mackenzie HS. Nephron mass as a risk factor for progression of renal disease. Kidney Int Suppl 1997;63:S124-7.
23. Majumdar A, Vainio S, Kispert A, McMahon J, McMahon AP, Wnt11 and Ret/Gdnf pathways cooperate in regulating ureteric branching during metanephric kidney development. Development 2003;130:3175-85.
24. Sanyanusin P, Schimmenti LA, McNee LA, Ward TA, Pierpoint ME, Sullivan MJ, et al. Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. Nat Genet 1995;9:358-64.
25. Hahn H, Cho YM, Park YS, You HW, Cheong HI. Two cases of isolated diffuse mesangial sclerosis with WT1 mutations. J Korean Med Sci 2006;21:160-4.
26. Dreyer SD, Zhou G, Baldini A, Winterpacht A, Zabel B, Cole W, et al. Mutations in LMX1B cause abnormal skeletal patterning and renal dysplasia in nail patella syndrome. Nat Genet 1998;19:47-50.
27. Nishimura H, Yerkes E, Hohenfellner K, Miyazaki Y, Ma J, Hunley TE, et al. Role of the angiotensin type 2 receptor gene in congenital anomalies of the kidney and urinary tract, CAKUT, of mice and men. Mol Cell 1999;3:1-10.
28. Jain S, Encinas M, Johnson EM Jr., Milbrandt J. Critical and distinct roles for key RET tyrosine docking sites in renal development. Genes Dev 2006;20:321-33.
29. Polycystic kidney disease: the complete structure of the Pkd1 gene and its protein. The International Polycystic Kidney Disease Consortium. Cell 1995;81:289-98.
30. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, Saris JJ, et al. Pkd2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 1996;272:1339-42.
31. Wilson PD. Polycystic kidney disease: new understanding in the
pathogenesis. Int J Biochem Cell Biol 2004;36:1868-73.
32) Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol 2009;20:23-35.
33) Hildebrandt F, Otto E. Cilia and centrosomes: a unifying pathogenic concept for cystic kidney disease? Nat Rev Genet 2005;6:928-40.
34) Watnick T, Germino G. From cilia to cyst. Nat Genet 2003;34:355-6.
35) Ruano-Gil D, Coca-Payeras A, Tejedo-Mateu A. Obstruction and normal recanalization of the ureter in the human embryo. Its relation to congenital ureteric obstruction. Eur Urol 1975;1:287-93.
36) Yang SP, Woolf AS, Quinn F, Winyard PJ. Deregulation of renal transforming growth factor-beta1 after experimental short-term ureteric obstruction in fetal sheep. Am J Pathol 2001;159:109-17.
37) Belk RA, Thomas DF, Mueller RF, Godbole P, Markham AF, Weston MJ. A family study and the natural history of prenatally detected unilateral multicystic dysplastic kidney. J Urol 2002;167:666-9.
38) Poucell-Hatton S, Huang M, Bannykh S, Benirschke K, Masliah E. Fetal obstructive uropathy: patterns of renal pathology. Pediatr Dev Pathol 2000;3:223-31.
39) Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet 1997;17:384-5.
40) Kolatsi-Joannou M, Bingham C, Ellard S, Bulman MP, Allen LI, Hattersley AT, et al. Hepatocyte nuclear factor-1beta: a new kindred with renal cysts and diabetes and gene expression in normal human development. J Am Soc Nephrol 2001;12:2175-80.
41) Ma Z, Gong Y, Patel V, Karner CM, Fischer E, Hiesberger T, et al. Mutations of HNF-1beta inhibit epithelial morphogenesis through dysregulation of SOCS-3. Proc Natl Acad Sci USA 2007;104:20386-91.
42) Dressler GR, Wilkinson JE, Rothenpieler UW, Patterson LT, Williams-Simons L, Westphal H. Deregulation of Pax-2 expression in transgenic mice generates severe kidney abnormalities. Nature 1993;362:65-7.
43) Jenkins D, Woolf AS. Uroplakins: new molecular players in the biology of urinary tract malformations. Kidney Int 2007;71:195-200.